Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 110 results.

Thumbnail for Deep Remission, Delayed Immunity: Prospective Characterization of Normal B-Cell Reconstitution After Venetoclax Based Therapy in CLL and its Implications for Vaccination.

CLL - 880

Deep Remission, Delayed Immunity: Prospective Characterization of Normal B-Cell Reconstitution After Venetoclax Based Therapy in CLL and its Implications for Vaccination.

Chantal Saberian

Poster Presenter: Chantal Saberian

$Thumbnail for Efficacy and Safety of CAR T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis$

CLL - 888

Efficacy and Safety of CAR T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis

Hira Cheema

Poster Presenter: Hira Cheema

Thumbnail for Fondaparinux vs Argatroban for Heparin-Induced Thrombocytopenia in Patients With Hematologic Malignancies: A Propensity-Matched Real-World Analysis

CLL - 895

Fondaparinux vs Argatroban for Heparin-Induced Thrombocytopenia in Patients With Hematologic Malignancies: A Propensity-Matched Real-World Analysis

Ahmed Abbasi

Poster Presenter: Ahmed Abbasi

Thumbnail for Real-World Outcomes of Pirtobrutinib Versus Venetoclax After Covalent BTK Inhibitor Exposure in CLL/SLL

CLL - 916

Real-World Outcomes of Pirtobrutinib Versus Venetoclax After Covalent BTK Inhibitor Exposure in CLL/SLL

Vishw Patel

Poster Presenter: Vishw Patel

Thumbnail for Non-CLL-type MBL and CHIP are Associated Precursor Conditions: Insights from Mayo Clinic's MBL Screening Cohort

CLL - 939

Non-CLL-type MBL and CHIP are Associated Precursor Conditions: Insights from Mayo Clinic's MBL Screening Cohort

Yuan Yao

Poster Presenter: Yuan Yao

Thumbnail for Peripheral Blood Inflammatory Markers as Prognostic Indicators in Chronic Lymphocytic Leukemia

CLL - 951

Peripheral Blood Inflammatory Markers as Prognostic Indicators in Chronic Lymphocytic Leukemia

Chiara Maria Rapolla

Poster Presenter: Chiara Maria Rapolla

Thumbnail for Efficacy, Safety, and Resistance in Pirtobrutinib-Treated CLL/SLL After Covalent BTK Inhibitor Failure: A Systematic Review of the BRUIN Trial Program

CLL - 963

Efficacy, Safety, and Resistance in Pirtobrutinib-Treated CLL/SLL After Covalent BTK Inhibitor Failure: A Systematic Review of the BRUIN Trial Program

Kolluri Prathyusha

Poster Presenter: Kolluri Prathyusha

Thumbnail for Cardiovascular, Bleeding, and Mortality Outcomes with Acalabrutinib vs. Zanubrutinib in Chronic Lymphocytic Leukemia: A Real-World Analysis from the Epic Cosmos Federated EHR Network

CLL - 967

Cardiovascular, Bleeding, and Mortality Outcomes with Acalabrutinib vs. Zanubrutinib in Chronic Lymphocytic Leukemia: A Real-World Analysis from the Epic Cosmos Federated EHR Network

Abat Khan

Poster Presenter: Abat Khan

Thumbnail for Trends in Mortality Associated with Leukemias and Heart Failure Among Adults Aged =25 Years in the United States, 1999-2025: A CDC WONDER Analysis

CLL - 975

Trends in Mortality Associated with Leukemias and Heart Failure Among Adults Aged =25 Years in the United States, 1999-2025: A CDC WONDER Analysis

Anusha Kalluru

Poster Presenter: Anusha Kalluru

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.